Delivery Order SPE2DR25D1100-SPE2DR26FCL9F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,752.23 to AmerisourceBergen Drug Corp for Pegasys 180 mcg/0.5 mL syringes on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price contract, which was not set aside for small business or other designated categories, represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,752.22 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Pegasys 180 mcg/0.5 mL syringes. This is a firm fixed price contract with an ultimate completion date of August 22, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was competitively awarded. Performance will take place at the...
- This delivery order, valued at $6,855.38, was awarded to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Pegasys 180 mcg/0.5 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-set-aside award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under a child contract structure, leveraging the...
- The Defense Logistics Agency awarded a $1,381.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for Pegasys 180 mcg/mL vials. This is a non-set-aside, competitively awarded contract with performance in Conshohocken, Pennsylvania, and an ultimate completion date of September 16, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $2,072.25 delivery order to AmerisourceBergen Drug Corp for Pegasys 180 mcg/ml vials, with an ultimate completion date of September 15, 2025. This competitively awarded, non-set-aside contract reflects firm fixed pricing for pharmaceutical supply fulfillment. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $3,990.37 to AmerisourceBergen Drug Corp for the supply of Pegasys 180 mcg/ml vials. This competitively awarded, firm fixed-price delivery order was issued on August 25, 2025, with an ultimate completion date of August 26, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this pharmaceutical supply transaction. The award represents a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $6,833.83 on September 2, 2025, for Pegasys 180 mcg/mL vials to support the Defense Logistics Agency's Medical Supply Chain. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 3, 2025, with performance taking place at the contractor's Conshohocken facility. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,763.00 to AmerisourceBergen Drug Corp for Pegasys 180 mcg/mL vials, with an ultimate completion date of August 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with the DLA. This delivery...
- The Defense Logistics Agency awarded a $2,072.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Pegasys 180 mcg/mL vials, with an ultimate completion date of September 19, 2025. This non-set-aside competitive award was issued on September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,515.38 for Pegasys 180 mcg/ml vials on April 21, 2025, with completion scheduled for April 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the company's corporate office location in Conshohocken, PA. The award is funded by the Defense Logistics Agency's Medical Supply...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCL9FDelivery Order
The Defense Logistics Agency awarded a $5,800.84 delivery order to AmerisourceBergen Drug Corp for Pegasys 180 mcg/0.5 mL syringes on October 31, 2025, with an ultimate completion date of November 3, 2025. This is a firm fixed-price contract with no set-aside designation, executed through open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026 that supports military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal vendor for medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of pharmaceutical deliveries through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The SPE2DX IDC functions as a flexible contract vehicle enabling the company to fulfill diverse federal medical supply requirements, with DLA planning future Pharmaceutical Prime Vendor Global Program Generation V contracts that will involve multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 10/31/25 |